{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:37:05Z","timestamp":1747157825116,"version":"3.40.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Celgene Austria"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.clml.2015.07.645","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T07:00:24Z","timestamp":1438758024000},"page":"e143-e149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5326-8524","authenticated-orcid":false,"given":"Gregor","family":"Aschauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Linkesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"N\u00f6sslinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Stauder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Burgstaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fiegl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fridrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Girschikofsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Keil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.07.645_bib1","first-page":"635","article-title":"CC-5013 (Celgene)","volume":"5","author":"Mitsiades","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.clml.2015.07.645_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2015.07.645_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.07.645_bib4","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.07.645_bib5","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A\u00a0randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.645_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.07.645_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.07.645_bib8","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.07.645_bib9","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2015.07.645_bib10","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0145-2126(09)70010-4","article-title":"Myelodysplastic syndromes: update on classification","volume":"33","author":"Bennett","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.07.645_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev.med.051308.132852","article-title":"Myelodysplastic syndromes","volume":"61","author":"Scott","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clml.2015.07.645_bib12","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.leukres.2011.05.034","article-title":"Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion\u2014the GFM experience","volume":"35","author":"Le Bras","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.07.645_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/leu.2010.231","article-title":"Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q","volume":"25","author":"Mallo","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.07.645_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.seminhematol.2012.07.001","article-title":"Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes","volume":"49","author":"Giagounidis","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2015.07.645_bib15","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1002\/cncr.24575","article-title":"The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2015.07.645_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00277-009-0846-z","article-title":"Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression","volume":"89","author":"G\u00f6hring","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.07.645_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3324\/haematol.2011.045914","article-title":"Treatment with Lenalidomide does not appear to increase the risk of leukemia progression in lower risk myelodysplastic syndrome with 5q deletion. A comparative analysis by the GFM","volume":"97","author":"Ad\u00e8s","year":"2012","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.clml.2015.07.645_bib18","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0145-2126(07)70066-8","article-title":"Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion","volume":"31","author":"List","year":"2007","journal-title":"Leuk Res"},{"issue":"7 suppl 10","key":"10.1016\/j.clml.2015.07.645_bib19","first-page":"4","article-title":"Recent advances in the treatment of MDS","volume":"5","author":"List","year":"2007","journal-title":"Clin Adv Hematol Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015010770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015010770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T21:58:00Z","timestamp":1599429480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015010770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S2152265015010770"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.07.645","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.07.645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}